New Delhi, May 8:  

Natco Pharma has launched generic sofosbuvir 400 mg/velpatasvir 100 mg tablets used for the treatment of chronic hepatitis C in India.

The company has launched a generic version of sofosbuvir 400 mg/velpatasvir 100 mg fixed dose combination in India under the brand name ‘Velpanat’, Natco Pharma said in a BSE filing today.

The company’s product is a generic version of Gilead Sciences Inc’s Epclusa tablets.

Epclusa is used to treat adults with chronic hepatitis C genotype 1 to 6 with or without cirrhosis, Natco Pharma said.

Natco Pharma has priced its generic tablets at an MRP of Rs 18,500 for a bottle of 28 tablets in India, the company said.

The company “has signed a non-exclusive licensing agreement with Gilead Sciences Inc to manufacture and sell generic versions of its chronic hepatitis C medicines in 101 developing countries, it added.

Shares of Natco Pharma were trading up by 0.63 per cent at Rs 907.25 on the BSE.

(This article was published on May 8, 2017)
Post Comment

Get more of your favourite news delivered to your inbox

Please enter your email. Thank You.
Newsletter has been successfully subscribed.